TABLE 1.
Characteristics at baseline and follow‐up (n = 20). The ReShape CV‐Risk Study
| Baseline | 6 months' follow‐up | 2 years' follow‐up | P for within‐subject contrasts between baseline and 2 years | P for repeated measures | ||||
|---|---|---|---|---|---|---|---|---|
| Female sex, n (%) | 3 | (15) | ||||||
| Age, years | 54 | (±9) | ||||||
| Body mass index, kg/m2 | 31.9 | (±4.8) | 32.0 | (±5.1) | 32.0 | (±5.1) | .08 | .07 |
| Glycosylated hemoglobin, % | 5.6 | (±0.3) | 5.6 | (±0.3) | 5.6 | (±0.4) | .7 | .3 |
| Total cholesterol, mmol/l | 5.1 | (±1.2) | 5.0 | (±0.9) | 5.0 | (±1.0) | .8 | .9 |
| LDL cholesterol, mmol/l | 3.6 | (±1.1) | 3.4 | (±1.0) | 3.4 | (±1.0) | .1 | .2 |
| Office SBP, mm Hg | 164 | (±21) | 139 | (±19) | 151 | (±18) | .1 | .006 |
| Office DBP, mm Hg | 108 | (±20) | 89 | (±13) | 97 | (±13) | .06 | .005 |
| Mean ambulatory SBP, mm Hg | 156 | (±21) | 145 | (±14) | 147 | (±14) | .09 | .06 |
| Mean ambulatory DBP, mm Hg | 97 | (±14) | 89 | (±11) | 90 | (±11) | .04 | .007 |
| No. of BP lowering drugs | 4.5 | (4‐8) | 4.0 | (2‐6) | 4.0 | (0‐7) | .07 | .07 |
| Type of BP lowering drug, n (%) | ||||||||
| Calcium channel blocker | 17 | (85) | 17 | (85) | 17 | (85) | ||
| ACE inhibitor or ARB | 20 | (100) | 20 | (100) | 19 | (95) | ||
| Thiazide diuretic | 8 | (40) | 8 | (40) | 8 | (40) | ||
| Loop diuretc | 14 | (70) | 13 | (65) | 11 | (55) | ||
| Beta blocker | 15 | (75) | 15 | (75) | 15 | (75) | ||
| Mineralcorticoid receptor blocker | 10 | (50) | 6 | (30) | 8 | (40) | ||
| Other | 10 | (50) | 7 | (35) | 8 | (40) | ||
Data are mean (±SD), apart from No. of BP lowering drugs, which are median (min‐max).
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; DBP, diastolic blood pressure; LDL, low density lipoprotein; SBP, systolic blood pressure.